These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30448935)

  • 1. The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.
    Aygun D; Sahin S; Adrovic A; Barut K; Cokugras H; Camcıoglu Y; Kasapcopur O
    Clin Rheumatol; 2019 Apr; 38(4):1025-1030. PubMed ID: 30448935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry.
    Thiele F; Klein A; Windschall D; Hospach A; Foeldvari I; Minden K; Weller-Heinemann F; Horneff G
    Rheumatol Int; 2021 Apr; 41(4):751-762. PubMed ID: 33590331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses.
    Aeschlimann FA; Chong SL; Lyons TW; Beinvogl BC; Góez-Mogollón LM; Tan S; Laxer RM
    J Pediatr; 2019 Jan; 204():162-171.e3. PubMed ID: 30318371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting.
    Brunelli JB; Schmidt AR; Sallum AME; Goldenstein-Schainberg C; Bonfá E; Silva CA; Aikawa NE
    Mod Rheumatol; 2018 Mar; 28(2):264-270. PubMed ID: 28949278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologics register JuMBO. Long-term safety of biologic therapy of juvenile idiopathic arthritis].
    Minden K; Klotsche J; Niewerth M; Horneff G; Zink A
    Z Rheumatol; 2013 May; 72(4):339-46. PubMed ID: 23456365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
    Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
    Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register.
    McErlane F; Foster HE; Davies R; Lunt M; Watson KD; Symmons DP; Hyrich KL
    Rheumatology (Oxford); 2013 Oct; 52(10):1905-13. PubMed ID: 23873820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
    Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
    Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies.
    Horne A; Delcoigne B; Palmblad K; Askling J
    RMD Open; 2019; 5(2):e001055. PubMed ID: 31798956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.